This segment focuses on the research, development, and commercialization of therapies for lupus nephritis, a serious autoimmune disease affecting the kidneys. The primary product in this segment is LUPKYNIS (voclosporin), an FDA-approved treatment for adult patients with active lupus nephritis. Research and development activities include clinical trials to evaluate the efficacy and safety of voclosporin in various patient populations and disease stages. The company utilizes advanced pharmaceutical technologies and methodologies to ensure the quality and effectiveness of its products. The patient impact is significant, as LUPKYNIS provides a much-needed treatment option for a disease with high unmet medical needs, improving kidney function and reducing the risk of kidney failure. Aurinia has a strong market position in the lupus nephritis treatment space, with a competitive advantage due to its innovative therapy. Future opportunities include expanding the use of voclosporin and developing new treatments for other autoimmune diseases. Regulatory and clinical aspects are critical, with ongoing interactions with regulatory bodies like the FDA. Partnerships with companies like Otsuka Pharmaceutical Co., Ltd. support the commercialization and distribution of voclosporin in key markets.